Bio-Rad Laboratories Launches New Products to Detect Hereditary Hemochromatosis; Aid in the Prevention of Liver Cirrhosis, Diabetes, And Impotence

Apr 30, 2001, 01:00 ET from Bio-Rad Laboratories, Inc.

    HERCULES, Calif., April 30 /PRNewswire/ --
 Bio-Rad Laboratories (Amex:   BIO.A; BIO.B), a leading manufacturer of clinical
 diagnostic tests, instrumentation, software and quality control systems
 announced today the launch of its new DNA-based products, the mDx(R) line of
 Analyte Specific Reagents (ASR) for Hereditary Hemochromatosis. These are the
 only fully licensed reagents commercially available for detection of the
 disorder. Hereditary Hemochromatosis results in the excessive accumulation of
 iron in bodily organs which may cause cirrhosis of the liver, diabetes,
 congestive heart failure, liver cancer, arthritis, impotence and premature
 menopause.
     Hereditary Hemochromatosis is a common genetic disorder among people of
 Northern European descent. In the United States, approximately 32 million
 people (1 in 10) are carriers of the genetic trait. More than one million
 Americans (1 in 200) are clinically affected, but very few of those affected,
 only about two percent, are diagnosed. Bio-Rad's new Analyte Specific Reagents
 are used to detect the C282Y and H63D mutations that account for more than
 85% of all cases of the disorder. If detected early, Hereditary
 Hemochromatosis can be treated effectively by routine methods.
     Bio-Rad's Analyte Specific Reagents are available in two versions for use
 with different amplification technologies:  Linked Linear Amplification (LLA),
 Bio-Rad's proprietary method for amplification of nucleic acids, and PCR
 (Polymerase Chain Reaction)-based technology, available to laboratories
 licensed by Hoffman LaRoche to perform PCR.
     "Launching this product line is an important milestone for Bio-Rad," said
 John Goetz, Vice President of the company's Clinical Diagnostics Group,
 "because it enables all laboratories to offer Hemochromatosis testing
 according to their own individual needs. The high level of interest in these
 reagents reaffirms our enthusiasm for the market potential of Hemochromatosis
 testing."
     For product information please visit Bio-Rad's Molecular Diagnostics web
 site at www.mdx.bio-rad.com, or e-mail mdx@bio-rad.com for special inquiries.
 
     Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational
 manufacturer and distributor of life science research products and clinical
 diagnostics. It is based in Hercules, California, and serves more than
 70,000 research and industry customers worldwide through a network of more
 than 30 wholly owned subsidiary offices.
 
     Various statements made within this press release may constitute
 "forward-looking statements" for purposes of the Securities and Exchange
 Commission's "safe harbor" provisions under the Private Securities Litigation
 Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934.
 The forward-looking statements contained herein involve risks and
 uncertainties that could cause results to differ materially from the Company's
 expectations.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48439465
 
 

SOURCE Bio-Rad Laboratories, Inc.
    HERCULES, Calif., April 30 /PRNewswire/ --
 Bio-Rad Laboratories (Amex:   BIO.A; BIO.B), a leading manufacturer of clinical
 diagnostic tests, instrumentation, software and quality control systems
 announced today the launch of its new DNA-based products, the mDx(R) line of
 Analyte Specific Reagents (ASR) for Hereditary Hemochromatosis. These are the
 only fully licensed reagents commercially available for detection of the
 disorder. Hereditary Hemochromatosis results in the excessive accumulation of
 iron in bodily organs which may cause cirrhosis of the liver, diabetes,
 congestive heart failure, liver cancer, arthritis, impotence and premature
 menopause.
     Hereditary Hemochromatosis is a common genetic disorder among people of
 Northern European descent. In the United States, approximately 32 million
 people (1 in 10) are carriers of the genetic trait. More than one million
 Americans (1 in 200) are clinically affected, but very few of those affected,
 only about two percent, are diagnosed. Bio-Rad's new Analyte Specific Reagents
 are used to detect the C282Y and H63D mutations that account for more than
 85% of all cases of the disorder. If detected early, Hereditary
 Hemochromatosis can be treated effectively by routine methods.
     Bio-Rad's Analyte Specific Reagents are available in two versions for use
 with different amplification technologies:  Linked Linear Amplification (LLA),
 Bio-Rad's proprietary method for amplification of nucleic acids, and PCR
 (Polymerase Chain Reaction)-based technology, available to laboratories
 licensed by Hoffman LaRoche to perform PCR.
     "Launching this product line is an important milestone for Bio-Rad," said
 John Goetz, Vice President of the company's Clinical Diagnostics Group,
 "because it enables all laboratories to offer Hemochromatosis testing
 according to their own individual needs. The high level of interest in these
 reagents reaffirms our enthusiasm for the market potential of Hemochromatosis
 testing."
     For product information please visit Bio-Rad's Molecular Diagnostics web
 site at www.mdx.bio-rad.com, or e-mail mdx@bio-rad.com for special inquiries.
 
     Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational
 manufacturer and distributor of life science research products and clinical
 diagnostics. It is based in Hercules, California, and serves more than
 70,000 research and industry customers worldwide through a network of more
 than 30 wholly owned subsidiary offices.
 
     Various statements made within this press release may constitute
 "forward-looking statements" for purposes of the Securities and Exchange
 Commission's "safe harbor" provisions under the Private Securities Litigation
 Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934.
 The forward-looking statements contained herein involve risks and
 uncertainties that could cause results to differ materially from the Company's
 expectations.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48439465
 
 SOURCE  Bio-Rad Laboratories, Inc.